コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ior alternative to the present standard (ie, haemodialysis).
2 toneal scarring, and premature transition to haemodialysis.
3 to quantitatively evaluate the initiation of haemodialysis.
4 ccess grafts are the best option for chronic haemodialysis.
5 als of patients infected with HCV who are on haemodialysis.
6 atients with organ transplants or who needed haemodialysis.
7 no acid metabolism and insulin resistance in haemodialysis.
8 ticoagulation, as they would be for standard haemodialysis.
9 dies were performed before, during and after haemodialysis.
10 te and renal function tests before and after haemodialysis.
11 rvival of patients is now equal to that with haemodialysis.
12 favoured vascular access choice for extended haemodialysis.
13 of vascular access that allows provision of haemodialysis.
14 ss to insomnia interventions for patients on haemodialysis.
15 mortality in patients receiving maintenance haemodialysis.
16 re when compared with conventional high-flux haemodialysis.
17 on population (pmp) to 4.8 pmp (P<0.001) for haemodialysis, 1.4 pmp to 1.6 pmp for peritoneal dialysi
18 costs of KRT were: US$19 380 per person for haemodialysis, $18 959 for peritoneal dialysis, and $26
19 ncreased from 27% in 2019 to 28% in 2023 for haemodialysis, 23% to 28% for peritoneal dialysis, and 3
21 ing five patients had grafts functioning for haemodialysis 6-20 months after implantation, and a tota
22 vessels seem to provide safe and functional haemodialysis access, and warrant further study in rando
24 ver, options for chronic vascular access for haemodialysis - an essential part of kidney replacement
26 1 randomised 93 patients who were undergoing haemodialysis and being treated with non-iron-based phos
27 cluding peritoneal dialysis, continuous KRT, haemodialysis and hybrid therapy) to manage hyperammonae
28 mnia is common among patients on maintenance haemodialysis and may be exacerbated by the challenges o
29 in the provision of dialysis - particularly haemodialysis and most notably in high-income countries
31 have been reported in individuals undergoing haemodialysis and those with chronic kidney disease.
33 ts with renal failure undergoing maintenance haemodialysis are associated with insulin resistance and
35 ies allocated public funding to provide free haemodialysis at the point of delivery; use of this fund
36 pment cohort, whereas 504 patients who began haemodialysis between 2012 and 2013 were enrolled in the
37 rred type of vascular access for maintenance haemodialysis but it may contribute to maladaptive cardi
38 ey failure who are treated with intermittent haemodialysis, but the effects of this strategy on organ
41 the abnormalities, which were all reduced by haemodialysis, closely resembled those in normal axons d
42 pFAK(Tyr397) were significantly decreased in haemodialysis compared to controls, whereas Rac1 and Akt
43 ic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to rece
45 , comparing online haemodiafiltration versus haemodialysis designed to measure mortality outcomes.
49 ma and myeloma cast nephropathy who required haemodialysis for acute kidney injury and who received a
50 percentage of patients because of dropout to haemodialysis for inherent complications of peritoneal d
51 re widely considered preferable to in-centre haemodialysis for many patients with ESKD in settings wh
52 Patients with ESRD (n = 1281) who commenced haemodialysis from 2008 to 2011 were enrolled in the dev
53 Phenylalanine kinetics were reduced in the haemodialysis group at 30 and 60 min post meal ingestion
54 ed with in 559 patients (27.0%) treated with haemodialysis (hazard ratio 0.84 [95% CI 0.74-0.95]).
56 LV mass, can be observed following long-term haemodialysis (HD) and has been attributed to regression
57 valent among adults treated with maintenance haemodialysis (HD) and has profound negative effects.
58 femoral arteries caused by fluid loss during haemodialysis (HD) and to determine the direction and am
61 ients, because their removal by conventional haemodialysis (HD) is severely limited by their low free
66 erview of incidence, modality use (in-centre haemodialysis, home dialysis, or transplantation), and m
68 was then constructed using factors affecting haemodialysis initiation as input variables and 3-year s
71 e effects of haemodiafiltration and standard haemodialysis on all-cause and cause-specific mortality.
75 imates were stratified by dialysis modality (haemodialysis or peritoneal dialysis) and for the subpop
77 SKD worldwide who are treated with in-centre haemodialysis, overall survival is poor, but longer in s
79 ment, and can maintain anaemia management in haemodialysis patients when given intravenously at 4-wee
80 perform longitudinal blood sampling of ESKD haemodialysis patients with COVID-19, collecting samples
82 integrin-cytoskeleton linkage are reduced in haemodialysis patients, suggesting for the first time th
91 nal cohort study to highlight differences in haemodialysis practices that affect survival and the exp
94 brils extracted from patients suffering from haemodialysis-related amyloidosis and those formed by se
98 y failure who were treated with intermittent haemodialysis suggest that fast UF(NET) rates are also a
101 d-stage renal disease who had been receiving haemodialysis through an access graft that had a high pr
102 hysiological values from patients undergoing haemodialysis treatment in the Renal Unit of the Churchi
103 e UK to allow patients to have more frequent haemodialysis treatments in hospital and satellite haemo
104 ght in February, 1996, all 126 patients in a haemodialysis unit in Caruaru, north-east Brazil, develo
109 13.8] years) who were established on regular haemodialysis were fitted with a wearable haemodialysis
110 made from polysulfone hollow fibre for human haemodialysis, which has an inner diameter of 200 mum an
111 d improve the well-being of people receiving haemodialysis without necessitating significant clinical